Presentations
December 2022
Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-In-Class CD20xCD3 Bispecific IGM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022
December 2022
IGM-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile
64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022
December 2022
CD123 Directed IgM T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release
64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022
November 2022
Unleashing the Power of Valency: A broad coverage, Receptor Trapping mechanism realized by the IgM platform for the prevention and treatment of infectious diseases
World Antiviral Congress — November 28-December 1, 2022
June 2022
Dose Response Profile of IGM-2323, a CD20xCD3 IgM Bispecific T Cell Engager, in Translational Models Supports Phase 2 Dose Selection in Non-Hodgkin’s Lymphoma
European Hematology Association 2022 Hybrid Congress – June 9-12, 2022
April 2022
A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022
April 2022
High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022
April 2022
Enhanced NK and CD8+ T cell proliferation, tumor cytotoxicity and reversal of T cell exhaustion with IGM-7354, an anti-PD-L1 IgM antibody and IL-15 cytokine fusion
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022
April 2022
Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity
American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022